An interventional study of Sertraline in Depression, sponsored by Roxane Laboratories. Completed at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Roxane Laboratories (part of Hikma Pharmaceuticals) · Not applicable, Interventional, and Treatment
The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
8,240 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 38 is below the median of 84 across 6,869 interventional studies indexed under Depression.
Browse Depression studies →Roxane Laboratories is the lead sponsor of 99 studies on the registry; none are open to participants now.
First submitted before Roxane Laboratories became part of Hikma Pharmaceuticals.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Bioequivalence
Time frame: Baseline, Two period, Fourteen day washout
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sertraline